There is no treatment allocation. Patients administered aplelicib by prescription that have started before inclusion of the patient into the study will be enrolled.

There is no treatment allocation. Patients administered mono endocrine therapy by prescription that have started before inclusion of the patient into the study will be enrolled.

There is no treatment allocation. Patients administered chemotherapy by prescription that have started before inclusion of the patient into the study will be enrolled.

Locations of metastatic sited at study entry:

• Local
• Lung
• Liver
• Central nervous system (CNS)
• Bone
• Other

Menopausal status

• Premenopausal

  • Ovarian suppression
  • Ovarian ablation

• Perimenopausal

  • Ovarian suppression
  • Ovarian ablation

• Postmenopausal

Number of patients with comorbidities will be presented

PIK3CA mutation status

• Confirmed PIK3CA mutation
• Confirmed absence of PIK3CA mutation
• No data available

Proportions of patients receiving the pre-stablished treatments

Proportions (%) of patients by treatment sequence:

• ribociclib in 1st line --> alpelisib in 2nd line.
• alpelisib in 1st line --> ribociclib or other CDK4/6 inhibitor in 2nd line

Defined as the time from index date to the date of the first documented progression or death due to any cause. If a patient has not had an event, PFS will be censored at the date of the last adequate tumor assessment by local BC management guidelines.

Defined as the time from index date to date of death due to any cause. If a patient is not known to have died, then OS will be censored at the latest date the patient was known to be alive (on or before the cut-off date).

Defined as the time from index date to the date of initiation of chemotherapy in patient who did not receive chemotherapy for advanced breast cancer at the inclusion. The time to chemotherapy for patients who did not receive any chemotherapy will be censored at the end of follow-up period.

Proportion of patients with permanent discontinuation to becollected

Reason of treatment discontinuation (if initial treatment was discontinued)

• Cancer progression
• Adverse event
• Death
• Patient decision
• Other

Proportion of patients with dose adjustment will be collected

Reasons of dose adjustment will be collected

The changes from baseline to each visit where measured using QLQ-C30. EORTC-QLQ-C30 is a 30-item questionnaire developed to assess the quality of life of cancer patients. Subject's responses to 28 questions about their physical functioning, disease symptoms, global health status and utilities are scored on a 4-point scale (1=Not at all to 4=Very much), a low score indicates a high / healthy level of functioning. And the responses to 2 questions about health-related QoL are scored on a 7-point scale (1=Very poor to 7=Excellent), a high score indicates a high / healthy level of functioning.

Using linear transformation, raw scores are standardized, so that scores range from 0 to 100.

EQ-5D-5L is a standardized participant completed questionnaire that measures health-related quality of life and translates that score into an index value or utility score. EQ-5D-5L consists of two components: a health state profile and an optional visual analogue scale (VAS). EQ-5D health state profile is comprised of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: 1= no problems, 2= slight problems, 3=moderate problems, 4= severe problems, and 5= extreme problems. Higher scores indicated greater levels of problems across each of the five dimensions.